Advanced Filters
noise

Solid Tumor Clinical Trials

A listing of Solid Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,625 clinical trials
P Principal investigator

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD) profile, and an exploratory evaluation of antitumor activity in participants with advanced solid tumors, who have no available standard …

18 years of age All Phase 1
J Juan Jin Attending physician

Real-World Study of Young Patients With Solid Tumors in China

To evaluate organ preservation rates, fertility preservation, and long-term quality of life after treatment among young patients.

18 - 80 years of age All Phase N/A
C Clinical Trial Referral Office

Role of Gut Microbiome in Cancer Therapy

This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and …

18 - 99 years of age All Phase N/A
M Maria Swartz

The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors

The study investigates how the COVID-19 pandemic has impacted the psychological, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors. AYA cancer survivors have inferior long-term survival compared to the general population, and the negative impact of the global COVID-19 pandemic may be even …

18 - 39 years of age All Phase N/A

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.

18 years of age All Phase 1/2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

Background \- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a …

2 years of age All Phase N/A

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors. The study drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab …

18 years of age All Phase 1/2
S Site Public Contact

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is …

18 years of age All Phase 2
R Rodney Carter

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be …

18 years of age All Phase 1/2

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

18 years of age All Phase 1/2

Simplify language using AI